Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-02-27 · accession 0002048497-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-02-27 | BBNX | Hopman Mark | Chief Commercial Off | A - Grant | $0.00 | +109.1K | 140.3K | +350% | $0 |
| D | 2026-03-03 | 2026-03-02 | BBNX | Hopman Mark | Chief Commercial Off | S - Sale | $12.36 | -834 | 139.5K | -0.6% | -$10.3K |
| D | 2026-03-03 | 2026-02-27 | BBNX | Hopman Mark | Chief Commercial Off | A - Grant | $0.00 | +58.7K | 58.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-27 | A | A | 109,105 | $0.00 | 140,320 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. |
| 2 | Common | Common Stock | 2026-03-02 | S | D | 834 | $12.36 | 139,486 | D | — | — | (F3) The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2026-02-27 | A | A | 58,749 | $0.00 | 58,749 | D | $12.63 · — to 2036-02-26 | 58,749 Common Stock | (F4) The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. |